Dyne Therapeutics Statistics
Share Statistics
Dyne Therapeutics has 113.67M
shares outstanding. The number of shares has increased by 15.57%
in one year.
| Shares Outstanding | 113.67M |
| Shares Change (YoY) | 15.57% |
| Shares Change (QoQ) | 11.16% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 10,318 |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 14.86M, so 13.08% of the outstanding
shares have been sold short.
| Short Interest | 14.86M |
| Short % of Shares Out | 13.08% |
| Short % of Float | 15.04% |
| Short Ratio (days to cover) | 5.74 |
Valuation Ratios
The PE ratio is -6.99 and the forward
PE ratio is -3.28.
Dyne Therapeutics's PEG ratio is
0.48.
| PE Ratio | -6.99 |
| Forward PE | -3.28 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 3.52 |
| P/FCF Ratio | -7.53 |
| PEG Ratio | 0.48 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Dyne Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.6,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 15.6 |
| Quick Ratio | 15.6 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.08 |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,653,218.75 |
| Employee Count | 192 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -60.18% in the
last 52 weeks. The beta is 1.19, so Dyne Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -60.18% |
| 50-Day Moving Average | 10.64 |
| 200-Day Moving Average | 24.21 |
| Relative Strength Index (RSI) | 55.43 |
| Average Volume (20 Days) | 2,490,641 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -343.89M |
| Net Income | -317.42M |
| EBITDA | -315.18M |
| EBIT | -317.42M |
| Earnings Per Share (EPS) | -3.37 |
Full Income StatementBalance Sheet
The company has 435.45M in cash and 23.99M in
debt, giving a net cash position of 411.46M.
| Cash & Cash Equivalents | 435.45M |
| Total Debt | 23.99M |
| Net Cash | 411.46M |
| Retained Earnings | -949.93M |
| Total Assets | 721.07M |
| Working Capital | 655.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -292.37M
and capital expenditures -2.38M, giving a free cash flow of -294.75M.
| Operating Cash Flow | -292.37M |
| Capital Expenditures | -2.38M |
| Free Cash Flow | -294.75M |
| FCF Per Share | -3.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
